
Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab. The …
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

